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METHODOLOGY
Optimization of incubation conditions 
of Plasmodium falciparum antibody multiplex 
assays to measure IgG,  IgG1–4, IgM and IgE 
using standard and customized reference pools 
for sero-epidemiological and vaccine studies
Itziar Ubillos1, Alfons Jiménez1,2, Marta Vidal1, Paul W. Bowyer3, Deepak Gaur4,5, Sheetij Dutta6, Benoit Gamain7, 
Ross Coppel8, Virander Chauhan5, David Lanar6, Chetan Chitnis5, Evelina Angov6, James Beeson9, 
David Cavanagh10, Joseph J. Campo1, Ruth Aguilar1 and Carlota Dobaño1* 
Abstract 
Background: The quantitative suspension array technology (qSAT) is a useful platform for malaria immune marker 
discovery. However, a major challenge for large sero-epidemiological and malaria vaccine studies is the comparabil-
ity across laboratories, which requires the access to standardized control reagents for assay optimization, to monitor 
performance and improve reproducibility. Here, the Plasmodium falciparum antibody reactivities of the newly avail-
able WHO reference reagent for anti-malaria human plasma (10/198) and of additional customized positive controls 
were examined with seven in-house qSAT multiplex assays measuring IgG,  IgG1–4 subclasses, IgM and IgE against a 
panel of 40 antigens. The different positive controls were tested at different incubation times and temperatures (4 °C 
overnight, 37 °C 2 h, room temperature 1 h) to select the optimal conditions.
Results: Overall, the WHO reference reagent had low IgG2, IgG4, IgM and IgE, and also low anti-CSP antibody levels, 
thus this reagent was enriched with plasmas from RTS,S-vaccinated volunteers to be used as standard for CSP-based 
vaccine studies. For the IgM assay, another customized plasma pool prepared with samples from malaria primo-
infected adults with adequate IgM levels proved to be more adequate as a positive control. The range and magnitude 
of IgG and  IgG1–4 responses were highest when the WHO reference reagent was incubated with antigen-coupled 
beads at 4 °C overnight. IgG levels measured in the negative control did not vary between incubations at 37 °C 2 h 
and 4 °C overnight, indicating no difference in unspecific binding.
Conclusions: With this study, the immunogenicity profile of the WHO reference reagent, including seven immuno-
globulin isotypes and subclasses, and more P. falciparum antigens, also those included in the leading RTS,S malaria 
vaccine, was better characterized. Overall, incubation of samples at 4 °C overnight rendered the best performance for 
antibody measurements against the antigens tested. Although the WHO reference reagent performed well to meas-
ure IgG to the majority of the common P. falciparum blood stage antigens tested, customized pools may need to be 
used as positive controls depending on the antigens (e.g. pre-erythrocytic proteins of low natural immunogenicity) 
and isotypes/subclasses (e.g. IgM) under study.
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publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
The identification of immune correlates of protection and 
risk against malaria is particularly challenging when deal-
ing with a complex pathogen like Plasmodium falcipa-
rum, which has a proteome of over 5000 proteins (http://
www.plasm odb.org), some of them polymorphic and/or 
variant. Consequently, malaria infection induces a very 
broad and diverse antigen-specific immunoglobulin (Ig) 
subtype response [1, 2]. Although the crucial role of IgG 
antibodies in protective malaria immunity was demon-
strated long time ago [3, 4], the antigenic targets of these 
antibodies have not yet been identified. However, it is 
presumed that such IgG responses are primarily directed 
to antigens on the surface of the P. falciparum asexual 
blood stage (BS). Numerous immune-epidemiological 
surveys have reported significant associations between 
levels of BS-specific IgG antibodies and protection from 
clinical malaria [5–7]. However, most of these studies 
have only described the magnitude of IgG responses and 
little is known about their subtypes, quality and function-
ality. Thus, the mechanisms mediating antibody immu-
nity are not fully elucidated.
Early in vitro studies suggested that inhibitory IgG anti-
bodies may control P. falciparum growth in collaboration 
with monocytes through opsonic phagocytosis [8–10] or 
antibody-dependent cellular inhibition [11]. Collectively, 
studies have pointed to cytophilic IgG subclasses (IgG1 
and IgG3) as the main contributors to naturally-acquired 
immunity, suggesting that cells bearing Fc-g receptors 
are involved in protective immune mechanisms [12–16]. 
Recent studies have also highlighted the potential impor-
tance of IgM [17, 18] or IgE [19, 20] in malaria protection 
or risk, respectively, but these isotypes have been much 
less studied in the malaria field. Further studies address-
ing antibody isotypes, subclasses, and their antigenic 
breadth are needed to define correlates in natural and 
in artificial immunity induced by vaccines such as the 
RTS,S/AS01E and those based on attenuated sporozoites.
RTS,S/AS01E is the most advanced malaria vaccine in 
development globally [21], however the immune surro-
gates of protection, the mode of action, and how vaccina-
tion affects or is affected by naturally-acquired immunity, 
remain unclear. A better characterization of the malaria 
serological profile at the Ig isotype and subclass lev-
els could help address these questions. However, widely 
applicable standardized, miniaturized, multiplex, high-
throughput assays, able to measure all Ig isotypes and 
subclasses, have been lacking.
The quantitative suspension array technology (qSAT) 
is an optimal platform for malaria biomarker discovery. 
The qSAT is a mid-high throughput platform that allows 
measuring multiple antigen-specific antibodies (up to 
500) in small sample volumes and in one single reaction. 
To study the mechanisms of immunity in malaria, several 
in-house qSAT assays using panels of up to 15 P. falcipa-
rum antigens were previously developed to measure total 
IgG [22],  IgG1–4, IgM and IgE [23] and factors affect-
ing IgG assay variability evaluated (Ubillos et  al., pers. 
comm.). However, a major challenge in the development 
of serological tests has been the lack of standardized 
positive controls [24] to allow comparability of data gen-
erated in different assays and laboratories, particularly 
when assessing large antigenic panels and diverse anti-
body isotypes/subclasses in samples of heterogeneous 
origin. Recently, a P. falciparum-specific human serum 
reference reagent (10/198) stable at high temperature and 
up to 24 months of storage has been described [25] that 
reduced inter-laboratory variation. This WHO standard 
has been characterized by ELISA to contain IgGs that 
recognize the circumsporozoite surface protein (CSP) 
and a handful of P. falciparum antigens from different 
genotypes: the merozoite surface protein (MSP)-119 (K1 
strain), MSP-142 (3D7), MSP-2 (3D7), MSP-3 (K1), and 
the apical membrane antigen (AMA)-1 (3D7, FC27 and 
FP3). The malaria community would benefit from having 
wider information on antigenic recognition of this refer-
ence reagent.
In previous studies, antigen-coupled beads were incu-
bated with samples for 1 h at room temperature [22, 23, 
26, 27]. Temperature of incubation influences the anti-
gen–antibody affinity [28, 29] and 1 h might not ensure 
the appropriate association/dissociation equilibrium. 
Hence, expanded incubation times with lower (4  °C) 
and higher (37  °C) temperatures could affect the assay 
performance.
In this study, a broader antibody reactivity profile of the 
WHO reference reagent and other customized positive 
controls was examined with seven in-house qSAT anti-
body assays measuring IgG,  IgG1–4, IgM and IgE against a 
panel of 40 antigens, including P. falciparum proteins that 
are part of the RTS,S/AS01E vaccine. This information 
will be generalizable to other applications and large sero-
epidemiological and vaccine studies of sporozoite and BS 
antigen targets, being useful for the malaria research com-
munity as a whole. In addition, different sample incubation 
times and temperatures (4  °C overnight, 37  °C 2 h, room 
Keywords: Plasmodium falciparum, Quantitative suspension array technology, Multiplex, IgG, IgG1, IgG2, IgG3, IgG4 
subclasses, IgM, IgE, Reference reagent, Incubation conditions, Assay performance
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temperature 1 h) were tested to select the incubation con-
ditions rendering the optimal quantification range and 
higher sensitivity without increasing unspecific binding.
Methods
Antigens
A customized multiplex panel with 33 BS and 6 pre-
erythrocytic (PE) P. falciparum antigens was established 
(Table 1). The glycan α-Gal (Gala1–3GalB1–4GlcNAc-R), 
detected in the surface of sporozoites, was also included, 
as anti-α-Gal IgM antibodies have been associated with 
malaria protection [30]. In addition to P. falciparum 
antigens, the hepatitis B surface antigen (HBsAg, a com-
ponent of the RTS,S vaccine) was added, as the assays 
were intended to be used with samples from this vaccine 
trial. Also, bovine serum albumin (BSA) and glutathione 
S-transferase (GST) were added to the panel to control 
for background signal coming from unspecific binding to 
the BSA used to block the coupled beads, and to the GST 
present in some of the fusion proteins.
Coupling of antigens to microspheres
Coupling of carboxylated polystyrene microspheres was 
carried out as described elsewhere [26]. Briefly,  MagPlex® 
microspheres (Luminex Corp., Austin, Texas) with differ-
ent spectral signatures selected for each antigen, were 
washed with distilled water and activated with Sulfo-
NHS (N-hydroxysulfosuccinimide) and EDC (1-ethyl-
3-[3-dimethylaminopropyl]carbodiimide hydrochloride) 
(Pierce, Thermo Fisher Scientific Inc., Rockford, IL), both 
at 50  mg/mL, in activation buffer (100  mM Monoba-
sic Sodium Phosphate, pH 6.2). Microspheres were 
washed with 50 mM MES (4-morpholineethane sulfonic 
acid, Sigma, Tres Cantos, Spain) pH 5.0 or dPBS (Dul-
becco’s Phosphate Buffered Saline, Lonza) pH 7.0 to a 
10,000 beads/µL concentration, and coated with antigens 
at a concentration previously established in MES or PBS 
and incubated in a rotatory shaker overnight (ON) at 4 °C 
and protected from light. Microspheres were blocked 
with PBS-BN [PBS with 1% BSA and 0.05% sodium azide 
(Sigma, Tres Cantos, Spain)] and re-suspended in PBS-
BN to be quantified on a Guava PCA desktop cytom-
eter (Guava, Hayward, CA) to determine the percentage 
recovery after the coupling procedure. Antigen-coupled 
beads were validated in singleplex and multiplex by 
measuring IgG in serial dilutions of a positive control. 
Similar IgG MFI levels were obtained in singleplex and 
multiplex measurements, with a strong correlation for all 
antigens assessed  (R2 > 0.98; p < 0.05) (Additional file  1). 
Coupled beads were stored multiplexed at a concentra-
tion of 1000 beads/µL/antigen at 4 °C and protected from 
light.
Reference reagents and control samples
WHO Reference Reagent for anti-malaria (P. falciparum) 
human plasma (10/198) (referred as WHO reference rea-
gent). A pool derived from plasma donations collected at 
the Blood Bank from individuals based in Kisumu, Kenya, 
with a history of malaria. This reference reagent presents 
IgG reactivity to P. falciparum AMA-1, MSP-119, MSP-
142, MSP-2 and MSP-3 [25]. The reagent has been defi-
brinated and diluted (1:5) with deionized sterile water 
and filled into 1  mL/ampoules. Each ampoule has been 
lyophilized comprising a freeze-dried residue of diluted 
human plasma.
RTS,S vaccine positive control (referred as WHO-CSP 
pool). An RTS,S pool prepared with plasmas from 10 
Mozambican children vaccinated with RTS,S/AS02 with 
known high IgG titres to CSP at peak response [65] was 
added to the WHO reference reagent (1:50 WHO refer-
ence reagent + 1:100 RTS,S pool), creating a CSP and 
HBsAg antibody enriched WHO reference reagent.
Malaria primo-infected plasma pool (referred as IgM 
pool). A customized pool prepared with plasmas from 
20 malaria naïve European adults with known high anti-
malaria IgM levels after being experimentally infected 
with P. falciparum in a controlled human malaria infec-
tion (CHMI) trial [66]. To prepare the pool, we first 
selected the time point that elicited the highest IgM 
breadth of response to a panel of 20 BS and 1 PE antigens 
from the CHMI trials conducted in Barcelona (day 35) 
and Tübingen (day 84). Ten individuals from each trial 
with the highest IgM breadth of response were selected 
and pooled.
Negative control. A pool of plasma samples from 20 
Spanish malaria-naïve individuals.
RTS,S samples. Three samples from individuals partici-
pating in the RTS,S malaria vaccine phase 2b trial con-
ducted in Mozambique [65] were randomly selected. 
High, medium and low responders were defined by 
tertiles.
qSAT assay and incubation conditions tested
IgG,  IgG1–4 subclasses, IgM and IgE levels were meas-
ured in the WHO reference reagent and other custom-
ized pools against multiplexed P. falciparum antigens 
using the xMAP™ technology (Luminex Corp., Austin, 
Texas). Fifty microliter of multiplexed antigen-cou-
pled beads were added to a 96-well μClear® flat bot-
tom plate (Greiner Bio-One, Frickenhausen, Germany) 
at 1000  beads/analyte/well. To assess the optimal tem-
perature and duration of sample incubation for IgG and 
 IgG1–4 assays, 50  µL of WHO reference reagent at 11 
serial dilutions (1:3, starting at 1/150) and the negative 
control at 4 serial dilutions (1:2, starting at 1:50) were 
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Table 1 Antigens included in the multiplex qSAT panel
* Recombinant proteins used for the experimental assessment of the optimal temperature and time of samples incubation in the IgG assays. MSP-2 A corresponds to 
the CH150 strain and MSP-2 B to the Dd2 strain
 Antigens and genotype Life-cycle stage Rationale References
Pre-erythrocytic (PE)
 CelTOS Sporozoite Exposure to sporozoite [31, 32]
 CSP full length* Sporozoite Exposure to sporozoite and RTS,S specific [30, 33]
 CSP NANP repeat* GST-fused Sporozoite Exposure to sporozoite and RTS,S specific [35]
 CSP C-terminus* GST-fused Sporozoite Exposure to sporozoite [36]
 SSP2 or TRAP Sporozoite Representative of exposure to sporozoite [34, 37]
Liver stage
 LSA-1* Liver stage Liver stage antigen—infected hepatocytes [38, 39]
Blood stage (BS)
 AMA-1 3D7 (FMP2.1)* Merozoite Involved in erythrocyte invasion [40, 41]
 AMA-1 FVO (FMP009) Merozoite Involved in erythrocyte invasion [41]
 CyRPA full length Merozoite Involved in erythrocyte invasion [42]
 EBA-140 GST-fused Merozoite Involved in erythrocyte invasion [43]
 EBA-175 R2 PfF2 Merozoite Involved in erythrocyte invasion [44]
 EBA-175 R3–5* GST-fused Merozoite Involved in erythrocyte invasion [43]
 EXP-1 Merozoite Involved in erythrocyte invasion [45]
 MSP-1 Block 2 3D7* GST-fused Merozoite Involved in erythrocyte invasion [46]
 MSP-1 Block 2 hybrid GST-fused Merozoite Involved in erythrocyte invasion [47]
 MSP-1 Block 2 MAD20 GST-fused Merozoite Involved in erythrocyte invasion [46]
 MSP-1 Block 2 PA17 GST-fused Merozoite Involved in erythrocyte invasion [46]
 MSP-1 Block 2 RO33 GST-fused Merozoite Involved in erythrocyte invasion [46]
 MSP-1 Block 2 Well GST-fused Merozoite Involved in erythrocyte invasion [46]
 MSP-142 3D7* Merozoite Involved in erythrocyte invasion [41, 48]
 MSP-142 FVO Merozoite Involved in erythrocyte invasion [41, 48]
 MSP-2 full length B* GST-fused Merozoite Representative of exposure to BS [49]
 MSP-2 full length A* GST-fused Merozoite Representative of exposure to BS [49]
 MSP-3 3C Merozoite Representative of exposure to BS [49]
 MSP-3 3D7* Merozoite Representative of exposure to BS [50]
 MSP-5 Merozoite Representative of exposure to BS [51, 52]
 MSP-6* GST-fused Merozoite Representative of exposure to BS [53]
 P41 Merozoite Involved in erythrocyte invasion [54]
 RH1 Merozoite Involved in erythrocyte invasion [55]
 RH2 (2030) GST-fused Merozoite Involved in erythrocyte invasion [56]
 RH2 b240 Merozoite Involved in erythrocyte invasion [57]
 RH4.2 GST-fused Merozoite Involved in erythrocyte invasion [58, 59]
 RH4.9* Merozoite Involved in erythrocyte invasion [58, 59]
 RH5 Merozoite Involved in erythrocyte invasion [42, 60]
 PTRAMP Merozoite Involved in erythrocyte invasion [61]
 DBL-α Trophozoite Involved in cytoadherence [62]
Pregnancy-specific
 DBL1-DBL2 VAR2CSA Trophozoite Associated to placental malaria exposure and representa-
tive of maternally-transferred antibodies
[63]
 DBL3-DBL4 VAR2CSA* Trophozoite [64]
Other antigens
 HBsAg* NA Hepatitis B surface antigen
 α-Gal Involved in malaria protection [30]
Controls
 GST* Background Control fusion protein
 BSA* Background Control unspecific binding
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incubated against a panel of 14 P. falciparum antigen-
coated beads in a 96-well plate (Table  1). Plates were 
incubated in a rotatory shaker at 600 rpm and protected 
from light under three conditions: (i) 37  °C for 2  h; (ii) 
4 °C ON and (iii) room temperature (RT) for 1 h. For the 
IgM assay, 50  µL of the WHO reference reagent or the 
IgM pool were assayed in 15 serial dilutions (1:3, starting 
at 1/50) against a panel of 40 P. falciparum antigens plus 
HBsAg (Table 1). Plates were incubated at two different 
conditions: 37  °C for 2 h and 4  °C ON. IgE levels in the 
WHO reference reagent assayed at 8 serial dilutions (1:2, 
starting at 1/10) were also measured under two different 
incubation conditions: 37 °C for 2 h and 4 °C ON. Finally, 
using the WHO-CSP pool, 23 standard curves for IgG, 
IgG1, IgG3 and IgM were constructed; and 12 standard 
curves for IgG2 and IgG4 all of 18 serial dilutions (1:2, 
starting at 1:50). The standard curves were incubated at 
4  °C ON against a total of 40 antigens (Table  1). Beads 
coupled with BSA and GST were included in the panel as 
background controls to assess unspecific binding to BSA 
and GST. After the incubation, plates were washed with 
PBS-0.05% Tween 20 buffer using a manual magnetic 
washer platform (Bio-Rad, Hercules, CA, USA). Second-
ary antibodies were added as previously described [23]. 
Briefly, biotinylated anti-human IgG at 1:2500 (Sigma 
B1140, polyclonal), anti-human IgM at 1:1000 (Sigma 
B1265, polyclonal) anti-human IgG3 at 1:1000 (Sigma 
B3523, clone HP-6050), and anti-human IgG1 at 1:4000 
(Abcam ab99775, clone 4E3). For the IgG2, IgG4 and IgE 
assays, the secondary antibodies were unconjugated to 
biotin: mouse anti-human IgG2 at 1:500 (Thermo Fisher 
MA1-34755, clone HP6014), mouse anti-human IgG4 
at 1:8000 (Thermo Fisher MA1-80332, clone HP6025), 
and mouse anti-human IgE at 1:500 (Abcam ab99834, 
clone HP6029). All secondary antibodies were incubated 
60 min at RT and washed. In IgG2, IgG4 and IgE assays, a 
tertiary biotinylated goat anti-mouse IgG (Sigma B7401, 
polyclonal) was added and incubated 60 min at RT. Plates 
were washed as before and streptavidin-R-phycoerythrin 
at 1:1000 (Sigma, Tres Cantos, Spain) was added to all 
wells and incubated 30  min at RT. Plates were washed 
and beads re-suspended in 100 μL/well of PBS-BN, pro-
tected from light and stored ON at 4  °C to be read the 
next day. Plates were read using the Luminex  xMAP® 
100/200 analyser (Luminex Corp., Austin, Texas) and at 
least 50 microspheres per analyte were acquired per well. 
Results are expressed as Median Fluorescence Intensity 
(MFI).
RTS,S-induced antibodies were measured in 3 sam-
ples from RTS,S-vaccinated children with known high, 
medium and low responses, together with serial dilu-
tions of the WHO reference reagent or the IgM pool (1:3 
starting at 1:50 for IgG,  IgG1–4 and IgM, and 1:2 starting 
at 1:10 for IgE) and incubated at 4 °C ON. Samples were 
assayed in 4 serial dilutions (1:10) starting at 1:500 for 
IgG, in 3 serial dilutions (1:10) starting at 1:100 for IgM 
and IgG1, and in 2 serial dilutions (1:10) starting at 1:50 
for IgG2 and IgG4. Samples were not assayed for IgG3 or 
IgE.
Statistical analyses
To stabilize the variance, the analysis was done on 
 log10-transformed values of the MFI measurements. The 
correlation and reliability between the different sample 
incubation conditions for the IgG and  IgG1–4 subclasses 
measured in the positive control, the negative control 
and the blanks were evaluated. After the Shapiro–Wilk 
normality test was applied, differences between condi-
tions were assessed by Kruskal–Wallis test with posthoc 
Tukey test. Reliability was assessed by the interclass cor-
relation coefficient (ICC) [67]. Titration curves of anti-
body concentrations vs. MFIs per antigen were fitted 
using a five-parameter (5PL), a 4PL or an exponential 
logistic equation depending on the best yield, following 
the formula MFI = Emax + ((Emin − Emax)/((1 + ((Conc/
EC50)^Hill))^Asym)), where  EC50 is the half maximal 
effective concentration, Emin is the minimum response, 
Emax is the maximum response, Asym is the asymmetry 
factor and Hill is the slope factor [68], using the drLumi 
package [69]. We calculated the coefficient of variation 
(CV) of Emin, Emax and used the goodness of fit model 
to assess the fitting of the curves. All analyses were done 
using R version 3.4.1.
Results
Total IgG,  IgG1–4, IgM and IgE responses against RTS,S 
antigens in the WHO reference reagent compared to those 
measured in sera from RTS,S-vaccinated children
To assess the suitability of the WHO reference reagent as 
a positive control to capture all responses in the context 
of RTS,S vaccine studies, levels of IgG,  IgG1–4, IgM and 
IgE against the RTS,S-specific antigens (CSP full length, 
CSP NANP repeat and CSP C-terminus) were measured 
and compared to levels in sera from RTS,S-vaccinated 
children from a phase 2b trial with known IgG CSP titres 
[65] (Fig.  1). The WHO reference reagent and RTS,S-
vaccinees antibody responses to the whole antigenic 
panel (Table  1) are shown in the Additional file  2. The 
IgM pool and RTS,S-vaccinees IgM levels were also com-
pared (Fig. 1h and Additional file 2). The WHO reference 
reagent presented lower IgG, IgG1, IgG2, IgG4, and IgM 
levels to RTS,S antigens than samples from RTS,S-vacci-
nated children who had high CSP responses (Fig.  1a–d, 
g). Comparisons of IgG3 and IgE levels were not possi-
ble because these data were not available for RTS,S sam-
ples. The IgM pool presented higher IgM levels to RTS,S 
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antigens than the WHO reference reagent and the RTS,S 
samples. Consequently, we decided to prepare a custom-
ized positive control for the RTS,S immunological stud-
ies, containing 1:50 of the WHO reference reagent plus 
1:100 of pooled plasma from RTS,S-vaccinated children 
with high CSP titres (WHO-CSP pool). IgG responses 
were compared between the WHO-CSP pool and the 
WHO reference reagent (Additional file  3). In addition, 
the  EC50 ratio between positive controls  (EC50 WHO 
reference reagent/EC50 WHO-CSP) was calculated for 
RTS,S-specific antigens as a proxy measure of relative 
potency of the WHO-CSP pool to the WHO reference 
reagent (Additional file 4). The  EC50 ratio for the 3 CSP 
antigens was between 0.44 and 0.58 for IgG, IgG1 and 
IgG3, and close to 1 for IgG2 against CSP full length.
Fifteen proteins in the multiplex panel were GST-fused 
(Table  1). The WHO-CSP pool was reactive to GST 
because the sera from RTS,S vaccinees 1  month after 
primary vaccination had antibodies that cross-reacted 
with GST. However, even if the samples contained equal 
or higher levels of antibodies to GST, this did not impede 
to accurately measure anti-malarial antibodies to the 
GST fusion proteins, as shown in correlation analyses of 
GST vs. GST fusion proteins in plasmas from RTS,S vac-
cinees (Additional file 5).
Levels of total IgG,  IgG1–4 and IgM against multiple P. 
falciparum antigens plus HBsAg measured in the WHO-CSP 
pool
The WHO-CSP pool was used to generate IgG,  IgG1–4 
and IgM titration curves incubating at 4  °C ON in the 
context of an RTS,S immunology study. The level of 
response was antigen-dependent; the most immunogenic 
proteins (AMA-1 3D7 and FVO, MSP-142 3D7 and FVO) 
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Fig. 1 RTS,S-specific responses measured in the WHO reference reagent, IgM pool and samples from RTS,S-vaccinated children. The 3 samples from 
RTS,S vaccinated children were of high, medium and low CSP IgG titres. a–g IgG,  IgG1–4, IgM and IgE levels to RTS,S-specific antigens measured in 
the WHO reference reagent; IgG, IgG 1, IgG2 and IgG4 also measured in RTS,S-vaccinated children; h IgM levels to RTS,S-specific antigens measured 
in the IgM pool vs. RTS,S-vaccinated children. The plots represent the levels of antibodies measured in serial dilutions of the positive pools (1:3 
starting at 1:50 for IgG,  IgG1–4 and IgM; and 1:2 starting at 1:10 for IgE), and the RTS,S vaccinees samples (1:10 starting at 1:500 for IgG, 1:100 for IgM, 
1:50 for  IgG1–4; and 1:2 starting at 1:10 for IgE). Isolated dots represent the levels measured in the technical blanks
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gave saturated signals even at the 1:6.5 × 106 dilution 
(Fig. 2).
To further characterize the IgG subclass composition 
of the WHO-CSP pool, the ratios of  IgG1–4 subclasses 
to total IgG [MFI IgG subclass at dilution (i)/MFI total 
IgG at dilution (i) × 100] were measured (Fig.  3). The 
predominance of IgG subclasses also varied depend-
ing on the antigen. For example, IgG1 responses were 
dominant for HBsAg, LSA-1, MSP-5, P41, RH1, RH2, 
PTRAMP, RH4.2, RH4.9 and SSP2, whereas MSP-2 full 
length, MSP-1 block 2 and RH4 induced mainly IgG3. 
IgG subclass responses to AMA-1 (3D7 and FVO), CSP 
(C-terminus and NANP repeat), EXP-1, MSP-142 (3D7 
and FVO), MSP-3 and RH5 were dominated by IgG1 and 
IgG3.
Optimal temperature and time of incubation to measure 
IgGs against P. falciparum antigens using the WHO 
reference reagent
To assess the optimal temperature and time of incubation 
for the measurement of IgG and  IgG1–4 subclasses, the 
assay performance of the WHO reference reagent against 
a panel of 14 P. falciparum antigens (Table 1) under three 
different incubation conditions (4  °C ON, 37 °C 2 h and 
RT 1  h) was compared. IgG and  IgG1–4 assays varied 
depending on the incubation procedure, with the larg-
est difference between 4 °C ON and RT 1 h (p < 0.001) for 
IgG. No differences were found between these two incu-
bation conditions for IgG2, IgG3 and IgG4. Differences 
between 4  °C ON and 37 °C 2 h were only observed for 
IgG (p = 0.026). IgG and  IgG1–4 levels against BSA and 
blanks were not affected by the incubation conditions. 
The MFI levels of IgG and  IgG1–4 measured in the nega-
tive control only varied when comparing 4 °C ON vs. RT 
1  h (p < 0.001) for some of the antigens. Figure  4 shows 
examples of the results for IgG1, and the complete data 
set is in the Additional file 6. The incubation at 4 °C ON, 
on average, showed the highest MFIs in the first dilution, 
except for IgG4 and reached blank levels at the lowest 
dilution (Fig.  4 and Additional file  6). Negative control 
MFI levels were also higher at 4  °C ON compared to 
other conditions, however the difference with the WHO 
RH1 RH2 2030 RH2 b240 RH4.2 RH4.9 RH5 SSP2 or PTRAP
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CSP NANPrep CyRPA DBL−alpha DBL1−DBL2 DBL3−DBL4 EBA−140 EBA−175 R2
alpha−Gal AMA−1 3D7 AMA−1 FVO BSA CelTOS CSP C−term CSP full length
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Fig. 2 IgG,  IgG1–4 and IgM fitted curves using the WHO-CSP pool to the 40-antigen multiplex panel incubating at 4 °C ON. Lines and dots represent 
predicted levels from 5PL, 4PL or exponential regression equations from 23 titration curves for IgG, IgG1, IgG3 and IgM; and 12 curves for IgG2 and 
IgG4. Titration curves contained 18 serial dilutions (1:2) starting at 1/50 of the WHO-CSP pool to a panel of 39 P. falciparum antigens plus HBsAg, 
α-Gal, BSA and GST
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Fig. 3 Boxplots of ratios of  IgG1–4 subclasses to total IgG measured in the WHO-CSP pool. Ratios are composed with the median of the 23 titration 
curves for IgG, IgG1 and IgG3 and 12 curves for IgG2 and IgG4, for each dilution point. Boxes show medians and interquartile ranges. The red star 
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control
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reference reagent at same dilution was high enough to 
establish a positivity threshold (Fig. 4).
Correlations between incubation conditions for IgG 
and  IgG1–4 subclasses measured against all antigens in 
the WHO reference reagent and negative control showed 
a  r2 > 0.93 for all IgG and  IgG1–4 subclasses. The ICCs 
between incubation conditions for IgG and  IgG1–4 meas-
ured in the WHO reference reagent showed overall good 
reliability, being 0.91 (0.89–0.93) for IgG3, 0.88 (0.87–
0.89) for IgG1, 0.83 (0.79–0.86) for total IgG, 0.79 (0.74–
0.83) for IgG2 and 0.63 (0.53–0.72) for IgG4. However, as 
seen in Fig. 4 and Additional file 6, ICCs in the negative 
control were of lower reliability, being of 0.85 (0.78–0.9) 
for IgG4, 0.74 (0.64–0.82) for IgG2, 0.38 (0.23–0.53) for 
total IgG, 0.39 (0.23–0.54) for IgG1 and 0.11 (− 0.03–
0.14) for IgG3. Blank levels were similar between incu-
bation conditions (Fig.  4 and Additional file  6). Taking 
together these results, we chose the incubation at 4  °C 
ON as the optimal for the IgG assays.
Optimal temperature and time of incubation to measure 
IgM and IgE against P. falciparum antigens using the WHO 
reference reagent and an IgM customized pool
Incubation conditions to measure IgM and IgE 
responses against a panel of 38 P. falciparum antigens 
plus HBsAg, α-Gal, BSA and GST (Table 1) were tested 
using the WHO reference reagent and an alternative 
IgM pool. The IgM pool gave higher IgM responses and 
of higher range compared to those obtained with the 
WHO reference reagent for most of the antigens, espe-
cially AMA-1s, MSP-1s and CSPs (Fig. 5). Incubation of 
the IgM pool at 4 °C ON showed higher responses com-
pared to incubation at 37  °C 2  h (Additional file  7A), 
with 80% of the antigens studied (35/43) presenting a 
higher  EC50 (i.e. AMA-1 3D7  EC50 4 °C ON 3.64 ± 0.66 
and  EC50 37  °C 2 h 2.62 ± 0.96). The IgM responses of 
the negative control measured at first dilution were 
higher than those of IgG and IgG subclasses, but lev-
els dropped quickly after the first dilution. Overall, IgM 
pool responses showed higher difference to the negative 
control than those obtained with the WHO reference 
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Fig. 5 Fitted IgM curves to the 40-multiplex panel in the WHO reference reagent and the IgM pool compared to negative control and blanks under 
two different incubation conditions. Curves from 4PL or 5PL logistic model equation comparing IgM levels measured in the WHO reference reagent, 
the IgM pool, the negative control and the blanks. Isolated dots in purple represent the IgM levels measured in the technical blanks
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reagent (Fig.  5). Similar differences in IgM responses 
between incubation conditions were obtained with the 
WHO reference reagent, measuring higher levels when 
incubating at 4  °C ON than at 37  °C 2  h (Additional 
file  7B). IgM technical blanks were not affected by 
incubation conditions (Additional file  7A, B). Correla-
tions for IgM responses between incubation conditions 
were  r2 = 0.96 for both WHO reference reagent and 
IgM pool. For the IgE assay, there were no differences 
between incubation conditions (Additional file 7C).
The ICCs between antibody responses measured in the 
two incubation conditions with the WHO reference rea-
gent were 0.92 (0.91–0.93) for IgM and 0.82 (0.79–0.85) 
for IgE; and the ICC between conditions for the IgM 
assay using the IgM pool was 0.91 (0.9–0.92). However, 
IgM responses of negative controls showed moderate 
reliability between incubation conditions, having an ICC 
of 0.66 (0.57–0.73).
When comparing antibody levels measured in the 
WHO reference reagent vs. the IgM pool, there was 
moderate reliability, with ICC of 0.65 (0.61–0.769) at 4 °C 
ON, and 0.66 (0.61–0.7) at 37 °C 2 h, meaning that there 
was 35% of variability between reference pools. Con-
sidering the strong correlation and reliability of the two 
incubation conditions, but the higher IgM levels and MFI 
ranges obtained at 4 °C ON, this incubation was also cho-
sen for the IgM assay.
Discussion
A major challenge in large malaria sero-epidemiological 
and vaccine studies is to have access to consistent and 
unlimited control reagents that provide assay quality con-
trol and facilitate data consolidation. A universal malaria 
reference pool would be ideal to monitor performance 
of serological assays, improve inter-laboratory repro-
ducibility, make data from different studies comparable, 
and potentially give quantitative antibody measures. In 
this study, information was provided on the expanded 
antibody reactivity profile of the commercially available 
WHO reference reagent for anti-malaria (P. falciparum) 
human plasma (10/198) [25] and other customized posi-
tive controls by using seven in-house qSAT multiplex 
antibody assays to measure IgG,  IgG1–4, IgM and IgE 
against a panel of 40 antigens, including P. falciparum 
proteins that are part of the RTS,S/AS01E vaccine. In 
addition, different sample incubation times and temper-
atures (4  °C ON, 37  °C 2 h, RT 1 h) were tested for the 
qSAT assays to select the incubation conditions render-
ing the optimal quantification range and higher sensitiv-
ity without increasing unspecific binding. Data generated 
in this study will be useful for clinical malaria studies 
involving assessment of naturally-acquired immune 
responses as well as immunogenicity evaluation of CSP-
based vaccine candidates.
The estimation of malaria antibody concentration in 
multiplex assays is increasingly difficult. There are not 
appropriate standards or reference sera available that 
react strongly to complex antigen panels. Antibody 
concentrations have been previously estimated using 
an anti-human IgG curve [22, 23, 26, 27]. However, the 
binding system and the affinity of the anti-human IgG 
curve differ from that of antibodies in samples or posi-
tive controls. Thus, different assay conditions give differ-
ent slopes and curve parameters that could result in large 
deviations of concentration estimates. Thus, it has been 
recently reported that MFI responses measured indepen-
dently from a standard curve might reflect actual varia-
tion, while estimated concentration values are dictated 
by the precision of the standard curve [70]. As an alter-
native, the use of long positive control curves provide 
upper and lower asymptotes for most antigens, and allow 
establishing the linear quantification ranges, represent-
ing the optimal range to capture the breadth of antibody 
response in individual samples. However, a reference 
human serum pool with known levels of anti-P. falcipa-
rum antibody concentrations is highly desirable for the 
malaria community. The challenge remains in sourcing 
adequate serum/plasma pools that cover all antigens as 
panels become larger and more complex.
To test the immuneprofile of the WHO reference rea-
gent, antigen and isotype/subclass-specific curves con-
structed with serial dilutions of the reagent were fitted 
in non-linear equations, establishing the linear quanti-
fication ranges. Generation of curves with optimal lin-
ear quantification ranges is important to allow selecting 
the optimal dilution of test samples (lying on the linear 
range). In addition, the parameters of the curve may be 
used for the quality control of the assay. The WHO ref-
erence reagent is composed of samples from hyper-
immune individuals from a malaria endemic region [25], 
predominantly having anti-P. falciparum IgG1 and IgG3 
antibodies, rather than IgG2 and IgG4, reflecting the nat-
urally-acquired antibody patterns. Thus, for most anti-
gens, this pool is of restricted use to produce standard 
curves for IgG2, IgG4 or IgE antibodies, and this remains 
a limitation. Similarly, the WHO reference reagent might 
not be optimal for IgM measurements, particularly if 
high responses are expected in test samples. For this 
reason, a customized IgM pool with plasmas from naïve 
individuals experimentally challenged with P. falciparum 
at a time point when IgM predominated over IgG was 
prepared. This IgM pool proved to be very adequate for 
the generation of IgM titration curves in the study. Thus, 
as the WHO reference reagent has been established to 
measure IgGs, a reference standard to measure IgM 
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responses would still be lacking. Similarly, IgG2, IgG4 
and IgE specific reference standards would improve the 
reproducibility of the malaria-based immune assays.
This study also aimed to assess the usefulness of the 
WHO reference reagent as a positive control to gener-
ate titration curves in the context of RTS,S immunology 
studies. For this reason, samples from RTS,S vaccinated 
children with diverse CSP and HBsAg IgG titres were 
assayed together with the WHO reference reagent for 
comparison. It is important to test samples at several 
dilutions to maximize the assay sensitivity, but keeping 
to the minimum for cost-effectiveness, which is key in 
large sero-epidemiological studies. For this reason RTS,S 
samples were assayed at 4 dilutions for IgG, 3 dilutions 
for IgM and IgG1, and 2 dilutions for IgG2 and IgG4. 
Samples from RTS,S vaccinated children had signifi-
cantly higher CSP antibodies than individuals naturally-
exposed to P. falciparum sporozoites. Consequently, the 
WHO reference reagent could only be used to measure 
RTS,S-specific responses if a relative potency between 
the WHO reference reagent and the vaccinees samples 
was calculated [71]. Alternatively, data showed that the 
WHO reference reagent enriched with pooled sera from 
RTS,S-vaccinated children (WHO-CSP pool) [65] was 
adequate to capture all antibody responses, including the 
very high anti-CSP IgG levels in vaccinated children. To 
conserve the full reactivity of the WHO reference reagent 
to BS antigens, the WHO-CSP pool was constructed by 
adding half concentration of pooled plasmas from RTS,S 
vaccinated children (1:50 WHO reference reagent and 
1:100 plasma from RTS,S vaccinees), ensuring that RTS,S 
specific antibodies were increased without diluting other 
anti-P. falciparum antibodies. A proxy measure of rela-
tive potency of the WHO-CSP pool vs. the WHO refer-
ence reagent was estimated with  EC50. However, in 4PL 
and 5PL analysis, the dose–response is not the same over 
the entire tested concentration range, and the response 
changes relative to the concentration only in the mid-
dle part of the curves. Typically, these comparisons are 
made at the  EC50, however, these calculations are only 
valid under limited conditions. For instance, the dose–
response curve would need to have a common slope, and 
the maximum achievable response should be identical 
[72]. Unfortunately, these conditions are not met for the 
curves of most of the tested antigens and IgG subclasses. 
Similarly to CSP, it would be desirable to increase the 
WHO reference reagent reactivity to other P. falciparum 
PE antigens that are also vaccine candidates like SSP2/
TRAP, LSA-1 or CelTOS. Additionally, a second genera-
tion of the WHO reference reagent against other Plas-
modium species would be an advantage for other malaria 
immune studies in areas with P. vivax co-infections.
The WHO-CSP pool presented GST reactivity, mainly 
coming from the RTS,S samples, which poses the ques-
tion of whether the GST signal could be interfering with 
the responses to the GST-fused proteins. However, cor-
relation analysis showed that the antibody response to 
GST was not associated to the antibody response against 
the GST-fused protein and, therefore, that responses 
were independent. For example, CSP-specific antibod-
ies detected upon vaccination were very high and not 
interfered by anti-GST antibodies when using CSP GST 
fusion proteins as capture antigens. Because of these 
observations, the GST values were not subtracted during 
data pre-processing, and it was concluded that GST reac-
tivity was not a major part of the antibody signal to the 
P. falciparum portion of the fused proteins. Nevertheless, 
the GST reactivity with CSP pools remains an unsolved 
limitation that will be addressed in future studies upon 
the application of the assays to the analysis of samples 
from RTS,S vaccinated volunteers using GST fusion pro-
teins, e.g. by testing the blocking of the reactivity with 
soluble GST.
This first WHO reference reagent contains an arbitrary 
unitage of 100 Units per ampoule, however the concen-
trations of antibodies (IgG,  IgG1–4, IgM, IgE) specific 
to antigens such as those tested here remain unknown. 
Thus, it has been suggested to the WHO Expert Commit-
tee on Biological Standardization to assess the specific 
antibody concentrations in this reagent to allow absolute 
quantifications in future studies.
In a qSAT assay, temperature of incubation influences 
the reversible antigen–antibody kinetics by altering the 
constant association/dissociation equilibrium [29], which 
can impact assay sensitivity [73]. Raising the incubation 
temperature from 5 to 37 °C decreases the affinity of anti-
gen–antibody complexes by decreasing the stability of the 
docking complex [28, 74]. The conditions previously used 
in our laboratory for incubation of samples with antigen-
coupled beads were 1 h and RT [22, 23, 26, 27]. For this 
study, it was hypothesized that incubating samples for 
1  h might not ensure the appropriate association/disso-
ciation equilibrium. For this reason, expanded incuba-
tion times were tested and lower (4 °C) and higher (37 °C) 
temperatures were explored. Higher IgG and  IgG1–4 lev-
els were detected when the WHO reference reagent was 
incubated ON at 4 °C compared to 2 h at 37 °C or 1 h at 
RT. The ON incubation at 4  °C increased the IgG levels 
detected at high concentrations of the WHO reference 
reagent, but also the negative control. Yet, the difference 
between the WHO reference reagent and the negative 
control was large enough to establish a positive thresh-
old. Different incubation conditions showed small dif-
ferences for the WHO reference reagent performance, 
but larger differences for the negative control, indicating 
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more variability at very low IgG concentrations. The 
unspecific binding of IgGs to BSA-coupled beads or 
the background signal in the technical blanks was not 
affected by the incubation conditions, suggesting that the 
specificity of the IgG binding was not affected by incuba-
tion duration or temperature. For all these reasons, 4 °C 
ON was the incubation condition chosen for the anti-P. 
falciparum IgG and  IgG1–4 profiling of the WHO refer-
ence reagent and the WHO-CSP pool.
The optimal incubation condition for the IgM assay 
was assessed using the WHO reference reagent and the 
IgM pool. IgM levels were higher when incubating at 4 °C 
ON, although no significant differences were detected 
between incubating at 4 °C ON or 37 °C 2 h. Similarly to 
IgG and  IgG1–4 subclasses, IgM levels to BSA and blanks 
were low and not affected by the incubation condition. 
Based in these observations, 4 °C ON was also the incu-
bation condition chosen for the IgM assay.
The main limitation of the IgM assay was the high reac-
tivity of the negative control, also affected by the dura-
tion and temperature of incubation. IgMs are the first 
class of antibodies produced during a primary immune 
response. They are generated in the absence of apparent 
stimulation by specific antigens [75], and are thought to 
aid in the neutralization of pathogens prior to the devel-
opment of high affinity, antigen-specific antibodies [76]. 
Natural IgMs tend to have rather low antigen-binding 
affinities, compensated (to some extent) by their pen-
tameric nature. Thus, IgM is a highly polyreactive anti-
body [28] and cross-reactivity of IgMs with antigens from 
other pathogens to which they have been exposed, or 
even pathogens that have not yet been “seen” by the host 
immune system [77, 78], could account for the high reac-
tivity observed in the negative control. Additional tests 
are currently being performed to improve the specificity 
of the IgM qSAT assay.
Conclusion
This study served to expand the characterization of 
the immunogenicity profile of the WHO reference rea-
gent, including multiple Ig isotypes/subclasses, and sig-
nificantly more P. falciparum antigens, including CSP. 
The study also served to establish the optimal sam-
ple incubation condition for seven qSAT assays (4  °C 
ON). Some of the limitations of the WHO reference 
reagent were circumvented by preparing in-house or 
adapted pools to quantify high anti-CSP IgG and IgM 
responses. Information generated here is applicable 
to other malaria sero-epidemiological studies of PE 
and BS vaccine candidates, and thus valuable for the 
malaria research community.
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Additional files
Additional file 1. Correlations of antigen-specific IgG levels  (log10 MFI) 
between singleplex and multiplex coupled-beads measured in serial 
dilutions of a positive control pool. The positive pool was composed of 
plasmas from Mozambican adults with life-long exposure to malaria. The 
panel contained 26 antigens. The correlation coefficients  (r2) are indicated, 
and the blue line corresponds to the linear fit.
Additional file 2. Comparison of the WHO reference reagent, IgM pool 
and RTS,S samples responses to the 40-antigen multiplex panel incubat-
ing at 4 °C ON. IgG,  IgG1–4 subclasses, IgM and IgE were measured in the 
respective pools and samples. The plots represent the levels of antibodies 
measured in serial dilutions of the positive pools (1:3 starting at 1:50 for 
IgG,  IgG1–4 and IgM; and 1:2 starting at 1:10 for IgE), and the RTS,S samples 
(1:10 starting at 1:500 for IgG, 1:100 for IgM, 1:50 for  IgG1–4; and 1:2 starting 
at 1:10 for IgE). Data on IgG3 and IgE levels measured in RTS,S vaccinees 
were not available. Isolated dots represent the levels measured in the 
technical blanks.
Additional file 3. Comparison of the IgG and  IgG1–4 predicted curves 
between the WHO reference reagent and the WHO-CSP pool incubating 
at 4 °C ON. IgG and  IgG1–4 predicted curves from a non-linear equation 
were measured against a 23-multiplex panel. Isolated dots represent the 
levels measured in the technical blanks.
Additional file 4. IgG and  IgG1–4 50% effective concentrations  (EC50) to 
RTS,S-specific antigens measured in the WHO reference reagent and the 
WHO-CSP pool, and  EC50 ratios between pools. The functions used to fit 
the standard curves were 4PL (SSl4) or exponential (SSexp) equations.
Additional file 5. Correlations between GST vs. antigens included in the 
RTS,S vaccine, and GST vs. non-RTS,S antigens in plasmas from RTS,S-vac-
cinated children. Scatterplots with levels of IgG  (log10MFI) to GST alone in 
the X-axis and to GST-fused proteins (orange) or proteins not fused to GST 
(green) in the Y-axis. Linear regression lines with 95% confidence intervals 
(in grey) and Spearman correlation coefficients  (r2) for each antigen. Cor-
relations between IgGs to RTS,S proteins and GST were high but similar 
between GST-fused (CSP NANP & C-terminus) and non GST-fused proteins 
(CSP full length and HBsAg). Antibody levels against the GST-fused CSPs 
(Y-axis value) were higher than to the GST alone (X-axis value). IgG levels 
to GST fusion proteins representing non-RTS,S antigens (e.g. EBA-175, 
MSP-2) were not correlated with IgG levels to GST alone. There were low 
antibody responses to these antigens while there was a higher signal to 
the GST alone. Overall, the patterns of correlations were similar between 
GST-fused and non-GST fused proteins. Responses to GST and to GST 
fusion proteins appeared to be independent.
Additional file 6. Levels of IgG and  IgG2-4 to 15 antigens measured in the 
WHO reference reagent compared to negative control and blanks under 
three different incubation conditions. Curve plots of the antigen-specific 
antibody levels measured in serial dilutions of the WHO reference reagent, 
negative control and blanks at three different incubation conditions: 37 °C 
2 h (37 °C 2 h), 4 °C overnight (4 °C ON) and room temperature for 1 h (RT 
1 h). “neg” means negative control.
Additional file 7. Levels of IgM and IgE measured to the 40-multiplex 
panel in the WHO reference reagent and IgM pool compared to negative 
control and blanks under two different incubation conditions. Incuba-
tion conditions compared are: 4 °C (4 °C ON) vs 2 h at 37 °C (37 °C 2 h). A) 
Predicted 5PL curves of IgM levels in the IgM pool. B) Predicted 5PL curves 
of IgM levels in the WHO reference reagent. C) IgE levels in the WHO refer-
ence reagent.
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